Literature DB >> 22100470

Prevalence of validated risk factors for developing atrial fibrillation--can we identify high-risk ED patients?

Tyler W Barrett1, Stephanie A Couch, Cathy A Jenkins, Alan B Storrow.   

Abstract

OBJECTIVE: The aim of this study was to investigate whether emergency department (ED) patients who were newly diagnosed with atrial fibrillation (AF) displayed risk factors for incident AF on prior ED visits.
METHODS: This was a secondary analysis of a retrospective cohort study of ED patients with symptomatic AF at a tertiary referral center. We selected patients who were newly diagnosed with AF between July 1, 2005, and August 31, 2008, and had at least 1 ED visit before their diagnosis. We calculated the Framingham Heart Study AF risk score for each visit by documenting the presence of the risk factors (age, sex, body mass index, systolic blood pressure, hypertension treatment, PR interval, and ages of clinically significant cardiac murmur and heart failure diagnosis).
RESULTS: Of the 296 patients newly diagnosed with AF, 115 (39%) had at least 1 prior ED visit resulting in 454 ED visits for analysis. The median time from first to last visit was 4 years (interquartile range [IQR], 2.1-5.9). The median age was 66 years (IQR, 49-79 years). Home medications included antihypertensives in 81% of visits, and 60% of visits with available electrocardiograms had a PR interval of 160 milliseconds or more. Heart failure history was reported in 23% of visits. The median AF risk score was 8 (IQR, 4-10) corresponding to a 16% 10-year predicted risk.
CONCLUSIONS: Nearly 40% of patients diagnosed with new AF had previous ED visits and displayed validated risk factors for incident AF. The ED provides an opportunity to identify and educate these patients as well as refer them for primary prevention interventions.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22100470      PMCID: PMC3288846          DOI: 10.1016/j.ajem.2011.09.019

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  16 in total

Review 1.  Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention.

Authors:  R G Hart; J L Halperin
Journal:  Ann Intern Med       Date:  1999-11-02       Impact factor: 25.391

2.  Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.

Authors:  Jeff S Healey; Adrian Baranchuk; Eugene Crystal; Carlos A Morillo; Michael Garfinkle; Salim Yusuf; Stuart J Connolly
Journal:  J Am Coll Cardiol       Date:  2005-06-07       Impact factor: 24.094

3.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

Review 4.  Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials.

Authors:  Tong Liu; Panagiotis Korantzopoulos; Michael Shehata; Guangping Li; Xunzhang Wang; Sanjay Kaul
Journal:  Heart       Date:  2011-04-08       Impact factor: 5.994

Review 5.  Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop.

Authors:  Barry London; Christine Albert; Mark E Anderson; Wayne R Giles; David R Van Wagoner; Ethan Balk; George E Billman; Mei Chung; William Lands; Alexander Leaf; John McAnulty; Jeffrey R Martens; Rebecca B Costello; David A Lathrop
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

6.  Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.

Authors:  Emelia J Benjamin; Peng-Sheng Chen; Diane E Bild; Alice M Mascette; Christine M Albert; Alvaro Alonso; Hugh Calkins; Stuart J Connolly; Anne B Curtis; Dawood Darbar; Patrick T Ellinor; Alan S Go; Nora F Goldschlager; Susan R Heckbert; José Jalife; Charles R Kerr; Daniel Levy; Donald M Lloyd-Jones; Barry M Massie; Stanley Nattel; Jeffrey E Olgin; Douglas L Packer; Sunny S Po; Teresa S M Tsang; David R Van Wagoner; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2009-02-03       Impact factor: 29.690

7.  Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004.

Authors:  Alden J McDonald; Andrea J Pelletier; Patrick T Ellinor; Carlos A Camargo
Journal:  Ann Emerg Med       Date:  2007-04-27       Impact factor: 5.721

8.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.

Authors:  Roland E Schmieder; Sverre E Kjeldsen; Stevo Julius; Gordon T McInnes; Alberto Zanchetti; Tsushung A Hua
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

9.  Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study.

Authors:  Renate B Schnabel; Lisa M Sullivan; Daniel Levy; Michael J Pencina; Joseph M Massaro; Ralph B D'Agostino; Christopher Newton-Cheh; Jennifer F Yamamoto; Jared W Magnani; Thomas M Tadros; William B Kannel; Thomas J Wang; Patrick T Ellinor; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

10.  The effects of losartan on signal-averaged P wave in patients with atrial fibrillation.

Authors:  Masahiro Nomura; Tomohito Kawano; Kimiko Nakayasu; Yutaka Nakaya
Journal:  Int J Cardiol       Date:  2007-05-16       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.